Beschreibung
The design of novel drug delivery systems is becoming complementary to new drug discovery with the aim to reduce dosing frequency, to improve the compliance of the existing pharmacotherapy and to target viral reservoirs. Blood-tissue barriers prevent drug penetration and dampened the eradication of viral pools by ARV agents. The advances of highly active antiviral agents have led to reduction of viral load in plasma and mortality from AIDS. The basic requirement for the use of any drug against retrovirus related diseases is its bioavailability. Hence the aim of ARV therapy is now focused on reduction in the symptoms of disease progression to AIDS, elimination of HIV resting reservoirs, reducing the viral load to undetectable levels, minimizing the viral resistance, optimizing the drug therapy, reducing the adverse effects of the drugs and to improve the quality of life of the infected patients.
Autorenporträt
The author is a Research associate in dosage form development with novel drug delivery systems, specialized in extended release formulations of anti-viral drugs.She has to her credit many research publications in several international journals with impact factor and hold reviewer ship in leading peer - reviewed journals in the said field.
